Cardea 20/20
Handheld 12-lead ECG device for detecting cardiovascular issues in young athletes
Device · On PremiseCompany source
Company profile
About Cardiac Insight
Cardiac Insight, Inc. is a privately held medical device company based in Bellevue, Washington, renowned for its innovative cardiac diagnostic products. Founded by Dr. Dave Hadley and Dr. Vic Froelicher, the company has been providing cardiac evaluations since launching its first product in 2013. The company's flagship products include the Cardea 20/20, a handheld 12-lead ECG device that enhances electrocardiogram reliability for detecting cardiovascular issues in young athletes with the industry's lowest false-positive rate of approximately 2%, and the Cardea SOLO, introduced in 2017, a comfortable 7-day wearable ambulatory sensor with software-assisted ECG analysis. The Cardea SOLO system enables patients to record their ECG from home while providing fast, in-office software analytics that generate reports in under five minutes. In 2021, Cardiac Insight joined forces with global electronic components leader DreamTech, solidifying their position as a leading innovator in cardiac healthcare diagnostics. The company is committed to advancing sensor and algorithm development that prioritizes accuracy in analyzing high-quality ECG data, with a focus on making ECG analysis more accessible for healthcare providers and patients through streamlined efficiency, client-centric focus, and continuous innovation.
Company description Cardiac Insight official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Cardiac Insight?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- cardiac arrhythmias
- cardiovascular issues in young athletes
- sudden cardiac events
Who it serves
- Athletic Programs
- Healthcare Providers
- Patients
- Researchers
Deployment & integration
On Premise deployment with recorded integration context.
Geographic context
MarketsUSA
Company sourceOfficial website
Company milestones
Platform expansion
2021 partnership with DreamTech to solidify position as leading innovator in cardiac healthcare diagnostics
Partnerships
Recorded partners
- DreamTech (global electronic components leader, partnership established 2021)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Cardea SOLO
7-day ambulatory ECG monitoring system with in-office software analytics
Device · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
The Athlete's ECG: Sport-Specific Patterns, Physiological Remodeling, and Clinical Interpretation.JACC. Advances · Aug 20, 2026
Sex-specific electrocardiographic criteria for left ventricular hypertrophy in young athletes.Heart rhythm · Feb 1, 2026
Race- and Sex-Associated Electrocardiographic Repolarization Characteristics in Young American Athletes in the Digital Age.JACC. Advances · Jan 1, 2026
Distinct early repolarisation patterns in male Brazilian soccer players: insights from a multicentre study.Heart (British Cardiac Society) · Jun 26, 2025
Proposed enhanced recommendations for interpretation of electrocardiographic screening of athletes.Progress in cardiovascular diseases · Jan 1, 2025
Classification of Premature Ventricular Contractions in Athletes During Routine Preparticipation Exams.Circulation. Arrhythmia and electrophysiology · Sep 1, 2024
Clinical validation
Clinical-trial records
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After StrokeNCT03761394 · Mentioned · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Report generation time under 5 minutes
Cardea SOLO in-office analysis
False-positive rate ~2%
Cardea 20/20 automated 12-lead ECG system
Up to 7 days continuous monitoring
Cardea SOLO wear period
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Cardiac Insight
Recent articles published on Cardiac Insight's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.